Investor Presentaiton

Investor Presentation First six months of 2018 Slide 22 Sales growth driven by the diabetes franchise Novo Nordisk reported quarterly sales by therapy Reported sales split by product segments for first six months of 2018 Diabetes and obesity Haemophilia² Long-acting insulin NorditropinⓇ Other Human insulin Growth disorders Reported sales CAGR¹: 9.5% DKK billion 35 30 25 -2.2% 20 5.6% 15 10 3.4% 11.1% Premix insulin GLP-1 Fast-acting insulin Other diabetes and obesity Haemophilia Other biopharmaceuticals 6% 1% 19% 9% 7% 10% 10 5 0 Q2 2008 1 CAGR for 10-year period 2 Haemophilia comprises NovoSeven®, NovoThirteen®, NovoEight® and Refixia® changing diabetes® Q2 2018 22% 18% 9% Sales of DKK 54.3 billion (5%) novo nordisk

View entire presentation